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ABSTRACT The proﬁle of PC945, a novel triazole antifungal designed for adminis-
tration via inhalation, was assessed in a range of in vitro and in vivo studies. PC945
was characterized as a potent, tightly binding inhibitor of Aspergillus fumigatus sterol
14-demethylase (CYP51A and CYP51B) activity (50% inhibitory concentrations
[IC50s], 0.23 M and 0.22 M, respectively) with characteristic type II azole binding
spectra. Against 96 clinically isolated A. fumigatus strains, the MIC values of PC945
ranged from 0.032 to 8 g/ml, while those of voriconazole ranged from 0.064 to 4
g/ml. Spectrophotometric analysis of the effects of PC945 against itraconazole-
susceptible and -resistant A. fumigatus growth yielded IC50 (determined based on
optical density [OD]) values of 0.0012 to 0.034 g/ml, whereas voriconazole (0.019
to 1 g/ml) was less effective than PC945. PC945 was effective against a broad
spectrum of pathogenic fungi (with MICs ranging from 0.0078 to 2 g/ml), including
Aspergillus terreus, Trichophyton rubrum, Candida albicans, Candida glabrata, Candida
krusei, Cryptococcus gattii, Cryptococcus neoformans, and Rhizopus oryzae (1 or 2 iso-
lates each). In addition, when A. fumigatus hyphae or human bronchial cells were
treated with PC945 and then washed, PC945 was found to be absorbed quickly into
both target and nontarget cells and to produce persistent antifungal effects. Among
temporarily neutropenic immunocompromised mice infected with A. fumigatus intra-
nasally, 50% of the animals survived until day 7 when treated intranasally with
PC945 at 0.56 g/mouse, while posaconazole showed similar effects (44%) at 14 g/
mouse. This proﬁle afﬁrms that topical treatment with PC945 should provide potent
antifungal activity in the lung.
KEYWORDS Aspergillus fumigatus, azole, inhalation, CYP51, azole resistant, long
acting
The current management of the three major forms of aspergillosis, invasive asper-gillosis (IA), chronic pulmonary aspergillosis (CPA), and allergic bronchopulmonary
aspergillosis (ABPA) (1–4), involves prophylactic or therapeutic administration of tria-
zoles and, infrequently, surgical intervention (5). Existing antifungal medicines are
predominantly dosed either orally or systemically. These frequently exploited routes of
delivery are poor for treating airway disease, since drug concentrations achieved at the
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site of infection tend to be lower than those in other, healthy organs. This is especially
so for the liver, which is a site of triazole toxicity: up to 15% of patients treated with
voriconazole experience raised transaminase levels (6, 7). Exposure of the liver also
results in signiﬁcant drug interactions arising from triazole inhibition of hepatic P450
enzymes (8, 9).
It is evident that there is an unmet clinical need for improved antifungal therapies
which elicit fewer drug interactions, show reduced toxicity, achieve higher and more
sustained pulmonary drug concentrations, and also demonstrate potent activity against
azole-resistant Aspergillus strains. Thus, there are several advantages of topical treat-
ment over oral/systemic treatment which alter the risk-beneﬁt ratio of treatment
favorably. An optimized compound for topical delivery should have prolonged lung
tissue residence with limited systemic exposure to display a better adverse effect proﬁle
and to eradicate invasive aspergillosis due to a high-concentration exposure. We have
undertaken an extensive lead optimization program in order to identify potent azole
antifungal agents with optimal properties for topical administration to the lung,
including tissue retention and physicochemical properties required for formulation. In
this report, we disclose the in vitro and in vivo activity of PC945, which has the chemical
formula 4-[4-(4-{[(3R,5R)-5-(2,4-diﬂuorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)oxolan-3-
yl]methoxy}-3-methylphenyl)piperazin-1-yl]-N-(4-ﬂuorophenyl)benzamide (Fig. 1A) and
is a novel triazole antifungal agent designed speciﬁcally for inhaled administration (10).
RESULTS
CYP51-binding properties. PC945 produced type II difference spectra when
titrated against puriﬁed Aspergillus fumigatus CYP51A and CYP51B enzymes (AfCYP51A
and AfCYP51B) and bound to CYP51A with an afﬁnity similar to that of posaconazole
(Table 1; Fig. 1B). In contrast, in ligand titration experiments with puriﬁed CYP51B,
PC945 yielded a sigmoid binding saturation curve, while posaconazole gave the
expected tight-binding saturation curve (see Fig. S1 in the supplemental material). A
modiﬁed two-site allosteric model gave the best “off-the-shelf” ﬁt of the sigmoid PC945
saturation curve, yielding dissociation constant (Kd1 and Kd2) values of 19,298 M and
FIG 1 Efﬁcacy of PC945 as an inhibitor of A. fumigatus sterol 14-demethylases (CYP51 enzymes). (A)
Structure of PC945. (B) Type II azole binding spectra for A. fumigatus CYP51A and CYP51B. Each
experiment was performed 4 to 6 times, although data for only one replicate are shown. (C) Azole IC50
determinations for posaconazole () and PC945 (Œ). Mean relative velocity values are shown with
standard deviations. (D) Sterol composition of A. fumigatus treated with PC945. The relative levels of
lanosterol and eburicol are shown.
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0.32 M, respectively. This positive cooperative allosterism suggests either the exis-
tence of two nonequivalent ligand binding sites or the existence of two different
binding conformations/orientations for the PC945 molecule within CYP51B that are
responsible for the generation of the type II difference spectrum. Posaconazole bound
tightly to puriﬁed CYP51B, with a Kd value of 0.012 M.
Inhibitory activity against A. fumigatus CYP51 enzymes. The inhibitory activities
of PC945 and posaconazole against A. fumigatus sterol 14-demethylases were deter-
mined using 0.5 M AfCYP51A and 0.5 M AfCYP51B from the membrane fraction
prepared from Escherichia coli expression clones. Both PC945 and posaconazole were
strong, tightly binding inhibitors of CYP51A and CYP51B in vitro activity (Table 1; Fig.
1C), suggesting Ki.app values of 1 nM for both compounds (11). Moreover, PC945 was
as effective as posaconazole, and both agents appeared to share the same mode of
action, i.e., directly coordinating as the sixth axial ligand of the CYP51 heme iron. No
allosterism was observed during the inhibition of AfCYP51B activity by PC945.
Cell-based A. fumigatus sterol composition and CYP51 assay. Analysis of sterol
composition was performed by gas chromatography-mass spectrometry (GC-MS).
Treatment with increasing concentrations of either posaconazole or PC945, from 0 to
1 g ml1, resulted in the dose-dependent accumulation of the 14-methylated sterols
(lanosterol and eburicol) and the corresponding depletion of the ﬁnal sterol product,
i.e., ergosterol (Table 2; Fig. 1D).
We also investigated enzyme-inhibitory activity in a plate-based A. fumigatus cell-
based ergosterol assay. This test system takes advantage of the fact that cholesterol
oxidase can utilize ergosterol as a substrate, with a 65% loss of sensitivity. Oxidation of
ergosterol was determined by observing the conversion of the weakly ﬂuorescent
compound resazurin to the highly red ﬂuorescent compound resoruﬁn and was
normalized using crystal violet staining. With an inhibitor activity resembling that in the
cell-free model of CYP51, PC945 strongly inhibited ergosterol production (50% inhibi-
tory concentration [IC50]  0.0047 g/ml [0.0069 M]) and was 14- and 2.6-fold more
potent than voriconazole (IC50  0.067 g/ml [0.19 M]) and posaconazole (IC50 
0.012 g/ml [0.017 M]), respectively.
In vitro antifungal activity against azole-susceptible and azole-resistant strains
of A. fumigatus. The concentrations of test agents required to achieve 50% inhibition
(IC50) and 90% inhibition (IC90) (both determined based on optical density [OD]) of the
growth of a number of A. fumigatus strains (itraconazole-susceptible strains NCPF2010,
AF294, and AF293 and itraconazole-resistant strains AF72, AF91, and TR34/L98H) were
TABLE 1 Azole Kd and IC50 determinations versus A. fumigatus CYP51 (AfCYP51) enzymes
Test agent
Parameter value (M)a
AfCYP51A AfCYP51B
Kd IC50 Kd1 Kd2 IC50
PC945 0.50 0.23 19,298 0.32 0.22
Posaconazole 0.96 0.16 0.012 NA 0.17
aKd determinations used 4 M puriﬁed AfCYP51A and 4 M AfCYP51B. IC50 determinations used 0.5 M
AfCYP51A and 0.5 M AfCYP51B, recovered from the membrane fraction of E. coli expression clones. NA,
not applicable.
TABLE 2 Sterol composition of A. fumigatus treated with either posaconazole or PC945
Sterol
Sterol content in cells (%)
DMSO-treated
cells
Posaconazole-treated (g/ml) cells
DMSO-treated
cells
PC945-treated (g/ml) cells
0.0001 0.001 0.01 0.1 1 0.0001 0.001 0.01 0.1 1
Ergosterol 100 94.5 87.2 74.7 67.8 67.4 100 95.9 94.7 86.7 80.6 71.3
Ergost-5,7-dienol 0 3.3 3.9 0 0 0 0 4.1 2.5 3.3 0 0
Lanosterol 0 0 3.0 7.0 8.8 8.8 0 0 0 3.6 6.2 9.4
Eburicol 0 2.2 5.9 18.3 23.4 23.8 0 0 2.7 6.5 13.2 19.3
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calculated from growth curves generated using a modiﬁed 384-well EUCAST microdi-
lution method and compared to positive and negative controls. Overall, PC945 was
more active than all reference compounds, including voriconazole, posaconazole, and
itraconazole, against itraconazole-susceptible A. fumigatus strains (NCPF2010, AF294,
and AF293) (12, 13) (Table 3). In addition, PC945 was the most active test agent against
known itraconazole-resistant A. fumigatus strains (AF72 and AF91) (14, 15) (Table 3).
Against the A. fumigatus strain TR34/L98H, containing the environmentally acquired
TR34/L98H mutation (16), PC945, voriconazole, itraconazole, and caspofungin all failed
to achieve 90% inhibition of fungal growth, while posaconazole displayed an IC90 value
of 0.13 g/ml. However, PC945 achieved an IC50 of 0.034 g/ml against this strain,
thereby revealing it to be 2.5-fold more potent than posaconazole (Table 3). Bovine
serum albumin (BSA) supplementation was conﬁrmed to have no or little effect on the
MICs of voriconazole (2 g/ml without BSA, 1 to 2 g/ml with BSA), posaconazole (0.03
g/ml without BSA, 0.06 g/ml with BSA), itraconazole (0.25 g/ml without BSA, 0.125
g/ml with BSA), and amphotericin B (1 g/ml without BSA, 2 g/ml with BSA), using
A. fumigatus quality control strain ATCC 204305, but it showed marginal effects on the
MIC of PC945, a more lipophilic compound (0.25 g/ml without BSA, 0.0625 g/ml with
BSA).
In vitro antifungal activity against clinically isolated A. fumigatus strains. Test
agents were evaluated on 50 clinical isolates obtained from the St. Louis Hospital, Paris,
France, and on 46 clinical isolates obtained from the NW Mycology Centre, United
Kingdom. Based on the geometric mean, PC945 was found to be 2.5-fold more potent
than voriconazole but comparable to posaconazole (Table 4). Among the clinical
isolates from the NW Mycology Centre, 13 of the 46 strains were found to be posacona-
zole resistant, 7 of the 13 posaconazole-resistant isolates were conﬁrmed to be itra-
conazole resistant, and 2 of those were pan-azole resistant, including resistance to
voriconazole, based on the EUCAST epidemiological cutoff value (ECOFF). For 5 of the
posaconazole-resistant isolates, PC945 did not inhibit growth completely at concen-
trations of up to 8 g/ml. During this assay, the quality control strain A. fumigatus ATCC
204305 was used for validation. For this strain, posaconazole showed a MIC of 0.25
g/ml, within the range set by the EUCAST guidelines.
In vitro assessment of antifungal activity by use of CLSI methodology. Visual
assessment of the growth of four itraconazole-susceptible A. fumigatus strains demon-
strated that PC945 was the most potent compound tested, with an MIC value of 0.031
TABLE 3 Antifungal effects of PC945 and known antifungal agents in azole-susceptible and azole-resistant strains of A. fumigatusa
Strain Resistance mechanism
IC50 (IC90) (g/ml) of indicated agent
PC945 Voriconazole Posaconazole Itraconazole Amphotericin B Caspofungin
NCPF2010 None 0.0084 (0.010) 0.16 (0.20) 0.0086 (0.014) 0.057 (0.085) 0.23 (0.48) 0.11 (1)
AF294 None 0.0020 (0.0043) 0.082 (0.27) 0.0056 (0.011) 0.041 (0.052) 0.21 (0.79) 1 (1)
AF293 None 0.0012 (0.0041) 0.25 (0.74) 0.010 (0.028) 0.032 (0.23) 0.24 (0.85) 1 (1)
AF72 G54E mutation 0.0061 (0.029) 0.019 (0.062) 0.032 (0.19) 0.43 (1) 0.18 (0.64) 0.10 (1)
AF91 M220V mutation 0.0081 (0.059) 0.12 (0.38) 0.024 (0.12) 0.26 (1) 0.42 (1) 0.072 (1)
TR34/L98H TR34/L98H mutation 0.034 (1) 1 (1) 0.086 (0.13) 0.22 (1) 0.14 (0.29) 0.082 (1)
aIC50 and IC90 values were determined from optical density measurements.
TABLE 4 In vitro activities of PC945, posaconazole, and voriconazole against 96 clinically
isolated A. fumigatus strainsa
Test agent
MIC (g/ml)b
Range Geometric mean Mode MIC50 MIC90
PC945 0.032–8 0.17* 0.125 0.125 1
Voriconazole 0.064–4 0.42 0.5 0.5 1
Posaconazole 0.016–2 0.1 0.032 0.063 0.5
aAll MICs were determined visually.
b*, P  0.05 for PC945 versus the results for posaconazole (one-way ANOVA with Tukey’s test).
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g/ml, while voriconazole and posaconazole were less effective (Table 5). Thus, the
superiority of PC945 over voriconazole for A. fumigatus growth inhibition was con-
ﬁrmed by the CLSI method as well as the EUCAST microdilution method.
Antifungal activity against non-A. fumigatus species. The in vitro activities of
PC945, voriconazole, and posaconazole against 22 pathogenic fungi (1 or 2 isolates
each) are displayed in Table 6. The data for Aspergillus terreus show it to be more
susceptible to PC945 than to posaconazole. In addition, PC945 was found to have
antifungal activity against Aspergillus carbonarius and Aspergillus ﬂavus, although it was
less potent than posaconazole or voriconazole. Against Candida albicans (both azole-
susceptible and azole-resistant strains), Candida glabrata, and Candida krusei, PC945
was generally more active than voriconazole and shared equal potency with posacona-
zole. PC945, voriconazole, and posaconazole were comparable in their effectiveness
against Trichophyton rubrum. The remarkable potency of PC945 against Rhizopus oryzae
was seen in a greatly improved MIC (2 g/ml) compared to that of voriconazole and
posaconazole (8 g/ml). The potencies of PC945 against Cryptococcus neoformans
and Cryptococcus gattii were higher than or similar to those of voriconazole and
posaconazole. In contrast, Aspergillus niger, Aureobasidium pullulans, Penicillium chryso-
genum, Penicillium citrinum, Cladosporium argillaceum, Chaetomium globosum, Gibber-
ella zeae (Fusarium graminearum), Lichtheimia corymbifera, Mucor circinelloides, and
TABLE 5 Antifungal effects of PC945 and known antifungal agents on four itraconazole-
susceptible A. fumigatus strains, as determined using CLSI methodology
Test agent
MIC (g/ml)a,c MIC50 (g/ml)b,c
Median Interquartile range Median Interquartile range
PC945 0.031* 0.020–0.031 0.011** 0.0083–0.024
Voriconazole 0.5 0.5–0.5 0.14 0.082–0.15
Posaconazole 0.047 0.031–6.0 0.015 0.0095–0.016
aDetermined visually.
bDetermined using optical density measurements.
c*, P  0.05; **, P  0.01 for PC945 versus the results for voriconazole (Kruskal-Wallis one-way ANOVA with
Dunn’s test).
TABLE 6 Antifungal effects of PC945 and posaconazole on other fungal species
Species (strain[s])
No. of strains
tested
Culture
method
MIC (g/ml)a
PC945 Voriconazole Posaconazole
Aspergillus carbonarius (ATCC 8740) 1 CLSI 4 0.5 0.063
Aspergillus ﬂavus (ATCC 204304) 1 CLSI 8 2 0.13
Aspergillus ﬂavus (AFL8, NRRC3357) 2 EUCAST 6 0.63 0.16
Aspergillus niger (ATCC 1015) 1 EUCAST 8 1 0.20
Aspergillus terreus (AT49, AT7130) 2 EUCAST 0.078 1 0.093
Penicillium chrysogenum (ATCC 9480) 1 CLSI 8 2 0.13
Penicillium citrinum (ATCC 9849) 1 CLSI 8 8 0.5
Trichophyton rubrum (ATCC 10218) 1 CLSI 0.031 0.063 0.031
Aureobasidium pullulans (ATCC 9348) 1 CLSI 8 8 1
Cladosporium argillaceum (ATCC 38013) 1 CLSI 8 0.5 0.25
Candida albicansb (20240.047, ATCC 10231) 2 CLSI 0.081 0.14 0.081
AR Candida albicansb,c (20183.073, 20186.025) 2 CLSI 8.25 10 8.13
Candida glabratab (ATCC 36583, R363) 2 CLSI 0.5 8.13 0.5
Candida krusei (ATCC 6258) 1 CLSI 0.125 0.25 0.125
Chaetomium globosum (ATCC 44699) 1 CLSI 8 1 0.25
Gibberella zeae (Fusarium graminearum) (ATCC 16106) 1 CLSI 8 8 8
Cryptococcus gattii (clinical isolate) 1 EUCAST 0.25 0.125 0.5
Cryptococcus neoformans (ATCC 24067) 1 CLSI 0.008 0.016 0.016
Lichtheimia corymbifera (ATCC 7909) 1 CLSI 8 8 8
Mucor circinelloides (ATCC 8542) 1 CLSI 8 8 8
Rhizomucor pusillus (ATCC 16458) 1 CLSI 8 8 8
Rhizopus oryzae (ATCC 11145) 1 CLSI 2 8 8
aDue to the limited number of strains tested, the mean isolate MICs are presented.
bThe MIC given is the MIC50.
cAR, azole resistant (ﬂuconazole and voriconazole).
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Rhizomucor pusillus were not susceptible to PC945 treatment within the concentration
range tested.
In vitro determination of persistence of action. Retention of test agents within
the hyphae of A. fumigatus was determined using a resazurin-based microtiter assay.
The inhibition of fungal growth arising from continuous contact of the test compounds
with A. fumigatus hyphae for 16 h was measured and compared to that obtained after
contact with drug for only 20 min, followed by washout and incubation for the same
period. As shown in Table 7 and Fig. 2B, the antifungal potencies of voriconazole and
posaconazole diminished markedly after short contact and washout, by factors of
93-fold and 4.9-fold, respectively. In contrast, PC945 showed no change in its anti-
fungal activity between wash and nonwash conditions in this experimental paradigm
(Table 7). It was also observed that PC945 (IC50, 0.00010 g/ml) was 110- and 4.5-fold
more potent than voriconazole and posaconazole, respectively, at inhibiting hyphal A.
fumigatus growth.
In the second system, the persistence of action of PC945 was quantiﬁed using
galactomannan (GM) production in the supernatant as an index of fungal growth.
BEAS2B cells were infected with A. fumigatus, and the effects of a 24-h washout period
prior to infection were examined. A 1-h contact time with PC945 followed by a 24-h
washout resulted in an approximately 11-fold loss of potency against A. fumigatus
compared to that in the control assay in which there was no washout. Although
posaconazole showed a similar or slightly greater loss of potency on washout, it was
notable that voriconazole was ineffective after a 24-h washout. These data imply that
only a short period of contact of bronchial epithelial cells with PC945 would be required
for the agent to exhibit a long duration of therapeutic action (Table 7; Fig. 2C).
In vivo antifungal activity. The potential of intranasally administered PC945 as a
daily therapeutic treatment for pulmonary Aspergillus infection was investigated using
immunocompromised, temporarily neutropenic mice. In this model, 81% of control
mice (13/16 mice) were dead or had been removed from the study (“dropped out”) by
day 6 postinfection, and only 19% of mice survived (Table 8; Fig. 2D). However, we
observed that 50, 63, and 63% of mice dosed with PC945 (0.56, 2.8, and 14 g/mouse
[intranasal application of 0.016-, 0.08-, and 0.4-mg/ml suspensions, respectively]) sur-
vived (Table 8; Fig. 2D). In contrast, although the highest dose (70 g/mouse) gave a
75% survival rate, the effects of posaconazole at 2.8 and 14 g/mouse were weaker
than that of PC945 at 0.56 g/mouse (Table 8; Fig. 2E). Furthermore, the GM level in
bronchoalveolar lavage ﬂuid (BALF) collected on day 7 postinfection or on the day that
an animal dropped out of the study was signiﬁcantly reduced by treatment with PC945,
to a superior degree over that obtained with posaconazole treatment (Fig. 2F). Intra-
nasal A. fumigatus infection is known to cause “rolling” behavior in mice due to central
nervous system (CNS) effects via respiratory-systemic infection (17). In this study, it was
noted that PC945, but not posaconazole, substantially inhibited the incidence of this
rolling behavior (Fig. S2).
DISCUSSION
It has been demonstrated herein that PC945 is a potent antifungal agent that
possesses activity against a broad range of both azole-susceptible and azole-resistant
strains of A. fumigatus. Against itraconazole-susceptible A. fumigatus strains, PC945
TABLE 7 Potencies and persistence of action of PC945, posaconazole, and voriconazole
Test agent
Hyphae BEAS2B cells
IC50 (g/ml)a
Fold change
IC50 (g/ml)
Fold changeNo washout Washout No washout Washout
PC945 0.00010* 0.000086 0.87 0.0037 0.043 11.5
Voriconazole 0.011 1 93 0.054 1 18.6
Posaconazole 0.00045 0.0022 4.90 0.0031 0.046 14.7
a*, P  0.05 for PC945 versus the results for voriconazole (Kruskal-Wallis one-way ANOVA with Dunn’s test).
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showed an increase in potency between 20- and 180-fold over that of voriconazole,
with a comparable or improved potency versus that of posaconazole. In an itraconazole-
resistant strain of A. fumigatus with a CYP51A M220V mutation, obtained from a patient
undergoing high-dose itraconazole therapy, and an A. fumigatus strain harboring the
FIG 2 Antifungal activity of PC945 against A. fumigatus in vitro and in vivo. (A) A549 cells treated with PC945 or posaconazole
and infected with GFP-expressing A. fumigatus. Green, GFP-expressing A. fumigatus; blue, DAPI-stained nucleus; red,
CellTracker-stained cytoplasm. (B) Persistence of action of PC945 and voriconazole on A. fumigatus hyphae. (C) Persistence of
action of PC945 and voriconazole on human bronchial cells (BEAS2B cells) infected with A. fumigatus. (D and E) Effects of
once-daily intranasal treatment with PC945 (0.56, 2.8, or 14 g/mouse) and posaconazole (2.8, 14, or 70 g/mouse) on survival
of A. fumigatus-infected immunocompromised mice (n 8 to 16). (F) Galactomannan levels in BALF. Each horizontal bar shows
the mean  SEM for 8 mice per group. #, dead before day 7; ***, signiﬁcant difference from no infection (P  0.001); †††,
signiﬁcant difference from infection control (P  0.001).
TABLE 8 In vivo activities of PC945 and posaconazole
Test agent
Dose
(g/mouse)
No. of survivors on day 7/
total no. of mice (%)
Median days
of survival
Log rank (Mantel-Cox
test) P valuea
Vehicle 3/16 (19) 5
PC945 0.56 4/8 (50) 6 0.14
2.8 5/8 (63) 6.5 0.022*
14 10/16 (63) Undeﬁned 0.0095**
Posaconazole 2.8 1/8 (13) 5 0.69
14 7/16 (44) 6 0.050*
70 6/8 (75) Undeﬁned 0.0028**
a*, P  0.05; **, P  0.01.
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G54E mutation, recently discovered to be acquired environmentally (12, 18), PC945 was
6- and 2-fold more potent than voriconazole and posaconazole, respectively. Further-
more, in a strain of A. fumigatus isolated in France (16) and displaying the environ-
mentally acquired TR34/L98H mutation, PC945 was more active than voriconazole,
although it did not achieve 90% inhibition of growth.
Against 96 clinically isolated A. fumigatus strains obtained from St. Louis Hospital,
Paris, France, and the NW Mycology Centre, United Kingdom (Evotec UK Ltd.), the MIC
range for PC945 was found to be 0.032 to 8 g/ml, with a geometric mean of 0.17
g/ml, and the MIC50 and MIC90 values were 0.125 and 1.0 g/ml, respectively. The
potency of PC945 was superior to that of voriconazole and comparable to that of
posaconazole. It is noteworthy that out of 46 clinical isolates of A. fumigatus from the
NW Mycology Centre, 13 strains were posaconazole resistant and 2 were pan-azole
resistant, including having voriconazole resistance, based on the EUCAST ECOFF.
Several reports have demonstrated that there is an increasing incidence of itra-
conazole-resistant A. fumigatus in the northwestern region due to extensive clinical use
of itraconazole in this area of the United Kingdom (19, 20). PC945 showed inhibitory
activity against 8 of the 13 azole-resistant strains but did not completely inhibit the
growth of 5 strains when used at concentrations of up to 8 g/ml. Although the strains
are clearly resistant to azoles, the genetic cause(s) underlying resistance in these strains
is unknown.
In this study, we modiﬁed the original EUCAST system. First, for our in-house
screening regimen, we adapted the EUCAST methodology to a 384-well system, as this
is a more efﬁcient assay which has been shown for other fungal species to generate
data comparable to those obtained in the 96-well assay (21). The same ﬁnal concen-
tration of dimethyl sulfoxide (DMSO) was applied across the plate to compare treat-
ment effects with vehicle control effects more accurately; EUCAST currently suggests
dilution of compounds with EUCAST medium, but some lipophilic or insoluble com-
pounds may precipitate, generating misleading data. In fact, PC945 precipitated in
EUCAST medium at 4 g/ml, but voriconazole (less lipophilic) did not. Furthermore,
data from Pulmocide and from the St. Louis Hospital in Paris were generated by
supplementing the growth medium with 0.5% BSA, as this avoids the loss of lipophilic
compounds bound to plastic surfaces during the assay and is not inhibitory to A.
fumigatus growth (22, 23). Using the quality control strain A. fumigatus ATCC 204305,
we conﬁrmed that BSA supplementation did not affect the MICs of known antifungal
agents, including voriconazole, posaconazole, itraconazole, and amphotericin B. Lastly,
at Pulmocide we used turbidity, determined by assessment of OD by use of a spectro-
photometer, as a measure of fungal growth to enable more accurate quantiﬁcation of
the inhibitory effects of treatments. All the modiﬁcations described above helped to
quantify the antifungal activity of test agents more accurately.
While A. fumigatus represents a severe global health risk, other fungal species
continue to be equally problematic. Invasive candidiasis affects 46,000 people each
year in the United States alone, and an estimated 1 million people with HIV/AIDS
contract cryptococcal meningitis worldwide annually (24, 25). These ﬁgures underline the
pressing need for safer and more effective antifungals that deliver a broad spectrum of
activity. This report discloses that the novel agent PC945 has a broad activity proﬁle against
a diverse range of fungal species. The growth of C. albicans, C. glabrata, and C. krusei was
inhibited by PC945 as strongly as the inhibition with posaconazole and 1.7- to 16-fold more
actively than the inhibition with voriconazole. Against C. neoformans, PC945 was 2-fold
more potent than both voriconazole and posaconazole, while C. gattii was equally
susceptible to the inhibitory activities of PC945, voriconazole, and posaconazole.
Mucormycosis caused by R. oryzae has a mortality rate of 76% for patients with
pulmonary infections (26). In this study, PC945 was particularly effective against R.
oryzae (MIC value of 2.0 g/ml), while voriconazole and posaconazole had no effect
within the concentration range tested.
The proposed mechanism of action of PC945 is inhibition of sterol 14-demethylase
(CYP51A1), the enzyme required to convert eburicol to 14-demethylated eburicol, an
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essential step in the ergosterol biosynthesis pathway in fungi. Type II binding spectra,
which display an Amax at 423 to 430 nm and a broad trough at 386 to 412 nm, arise
through a speciﬁc interaction in which the triazole N-4 nitrogen (posaconazole) or the
imidazole ring N-3 nitrogen coordinates as the sixth axial ligand with the heme iron to
form a low-spin CYP51-azole complex (27, 28). PC945 produced type II difference
spectra when it was titrated against puriﬁed A. fumigatus CYP51A and CYP51B enzymes,
and it bound with an afﬁnity for CYP51A similar to that of posaconazole but yielded a
sigmoid binding saturation curve against CYP51B. The latter binding characteristic of
PC945 was not reﬂected in the compound’s inhibition of CYP51B activity, suggesting a
difference in the enzyme’s conformation in solution and that adopted when the
enzyme is incorporated into cell membranes. Furthermore, the strong inhibition of
CYP51A activity observed with both PC945 and posaconazole, indicative of tightly
binding inhibitors (with an IC50 approximately half the enzyme concentration present),
was tighter than predicted by the calculated Kd values from ligand binding studies
using recombinant CYP51A, suggesting that the conformation of puriﬁed CYP51A in
solution differs from that in cell membranes. In the sterol composition assay, treatment
with increasing concentrations of either PC945 or posaconazole, from 0 to 1 g ml1,
resulted in an accumulation of the 14-methylated sterols, lanosterol and eburicol, and
depletion of the ﬁnal sterol product, ergosterol; this is consistent with CYP51 inhibition
as the key pharmacological activity of both agents. In addition, the A. fumigatus
cell-based ergosterol assay demonstrated that PC945 was 14- and 2.6-fold more potent
at inhibiting ergosterol production than voriconazole and posaconazole, respectively.
Thus, the mechanism of action of PC945, as for other triazole antifungals, is the
inhibition of fungal sterol 14-demethylase, resulting in the depletion of ergosterol in
the fungal membrane and thereby disrupting membrane structure and function and
inhibiting growth of the pathogenic organism (29).
A highly desirable feature of topical medicines is a long duration of action ensuring
that the desired therapeutic activity is maintained throughout the interdose period. In
order to explore this parameter, the persistence of action of PC945 was studied in a
number of in vitro systems. For A. fumigatus hyphae, the IC50 measured for PC945
following a 20-min contact period and washout for 16 h was almost unchanged relative
to that obtained following continuous contact with the drug for the same period
without washout. Furthermore, in the BEAS2B cell line, washout for 24 h after a 1-h
contact period resulted in only an approximately 10-fold loss of potency against A.
fumigatus compared to that of the control, in which there was no washout period. This
property of cellular persistence in the absence of the pathogen may be a particularly
valuable property by enhancing the potential use of PC945 in prophylaxis.
The anti-Aspergillus activity of PC945 administered intranasally was also investigated
in mice by use of a survival readout. PC945 was dosed to animals pretreated with a
single round of cyclophosphamide and three rounds of hydrocortisone to induce
temporary neutropenia, followed 24 h later by inoculation with A. fumigatus. In this
study, 81% of vehicle-treated, A. fumigatus-infected mice were classiﬁed as dead/
dropped out by day 7. However, once-daily treatment with low-dose PC945 showed
marked beneﬁcial effects on survival. While 44% of infected mice survived to day 7
when treated with posaconazole at 14 g/mouse, those treated with PC945 showed
50% survival at a 25-fold lower dose (0.56 g/mouse). Despite our data displaying
similar antifungal activities as determined by the broth microdilution assay, these
results indicate that PC945 signiﬁcantly outperforms posaconazole in vivo. This superior
proﬁle probably arises from two factors, the ﬁrst pharmacokinetic and the second
pharmacodynamic. As discussed earlier, PC945 exhibits a longer duration of action than
that of posaconazole, and the molecule is retained within the lung, such that little
systemic exposure compared to that of posaconazole results after intranasal treatment
(unpublished data). As a clinical strategy, topical treatment of the lung is advantageous
over oral or intravenous therapy because it delivers high concentrations of an antifun-
gal agent directly to the site of infection and avoids unfavorable systemic side effects.
The beneﬁts of inhaled administration for the treatment of invasive pulmonary asper-
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gillosis have been shown in numerous studies involving amphotericin B, itraconazole,
and voriconazole (30–32).
Development of resistance to antifungal therapy has been an increasing problem in
recent years. It has been shown that a strategy for avoiding the development of
resistance is to ensure that the ratio of treatment peak concentration to MIC is
adequate (33). The relationship between resistance mutation induction and drug
exposure has been well studied in bacteria. In the case of levoﬂoxacin use against
infection with Pseudomonas aeruginosa, exposure at an area under the concentration-
time curve (AUC)/MIC ratio of 157 was calculated to prevent emergence of resistance
(34). In the same manner, delivery of antifungals directly to the lung enables high
AUC/MIC ratios to be achieved locally, reducing the risk of resistance.
PC945 is the ﬁrst antifungal speciﬁcally designed as a once-daily, topical, inhaled
treatment for Aspergillus infection of the lung. Designed to be retained within the
target organ (such as the lung), treatment with PC945 results in very low systemic
exposure (data not shown), thus reducing the potential risk for unwanted clinical
effects. In addition, PC945 exhibits high levels of plasma protein binding, further
reducing the likelihood of problems arising from circulating drug substance. Therefore,
PC945 has the pharmacological and pharmaceutical properties to be a best-in-class,
inhaled therapy for the treatment of A. fumigatus infection in humans.
MATERIALS AND METHODS
Antifungal agents. For in vitro antifungal assays, stock solutions of test agents were prepared in
DMSO (2,000 g/ml). For in vivo studies, test agents were suspended in physiological saline. PC945 was
synthesized by Sygnature Discovery Ltd. (Nottingham, United Kingdom), and voriconazole (Tokyo
Chemical Industry UK Ltd., Oxford, United Kingdom), posaconazole (Apichem Chemical Technology Co.,
Ltd., Zhejiang, China), itraconazole (Arkopharma, Carros, France), amphotericin B (Selleckchem, Munich,
Germany), and caspofungin (Selleckchem, Munich, Germany) were procured from commercial sources.
A. fumigatus CYP51 binding assay and enzyme-inhibitory activity. A. fumigatus CYP51 binding
properties were determined as described by Warrilow et al. (35). Test agents were titrated against 4 M
recombinant A. fumigatus CYP51A or CYP51B protein, and binding saturation curves were constructed
from the change in the absorbance between the spectral peak and the trough. A rearrangement of the
Morrison equation was used to determine the dissociation constant (Kd) values when ligand binding was
tight (36).
A CYP51 reconstitution assay system was used to determine 50% inhibitory concentrations (IC50s)
(37). Test agent was added to a mixture of 0.5 M CYP51, 1 M A. fumigatus cytochrome P450 reductase
isoenzyme 1 (AfCPR1), 50 M eburicol, 4% (wt/vol) 2-hydroxypropyl--cyclodextrin, 0.4 mg ml1
isocitrate dehydrogenase, 25 mM trisodium isocitrate, 50 mM NaCl, 5 mM MgCl2, and 40 mM 3-(N-
morpholino) propanesulfonic acid (MOPS) (pH 7.2). The mixtures were then incubated at 37°C for 10
min prior to initiation with 4 mM -NADPHNa4 followed by shaking for 20 min at 37°C. Sterol metabolites
were recovered by extraction with ethyl acetate followed by derivatization with 0.1 ml N,O-bis(tri-
methylsilyl)triﬂuoroacetamide:trimethylchlorosilane (99:1) and 0.3 ml anhydrous pyridine prior to anal-
ysis by gas chromatography-mass spectrometry.
A. fumigatus sterol analysis. A working suspension of A. fumigatus spores was prepared in
ﬁlter-sterilized MOPS-RPMI 1640 (RPMI 1640 medium containing 2 mM L-glutamine, 2% glucose, and
0.165 M MOPS, buffered to pH 7 with NaOH) to a ﬁnal concentration of 8  106 spores ml1. To each
100-mm petri dish, 10 ml of the working suspension was added, and the dishes were incubated for 4 h
at 35°C and 5% CO2. Samples for baseline determinations were collected by scraping, pelleted by
centrifugation at 2,000 rpm for 5 min, and stored at 80°C. Test compounds or DMSO (50 l) was added
to the remaining dishes, which were subsequently gently rocked by hand to disperse the compounds.
Dishes were incubated for 2 h at 35°C and 5% CO2. Samples were collected and processed as described
above. Posaconazole and PC945 concentrations of 0.0001, 0.001, 0.01, 0.1, and 1 g ml1 were tested.
These samples were prepared in the laboratory at Pulmocide Ltd. and sent to the laboratory at the Centre
for Cytochrome P450 Biodiversity, Institute of Life Science, Swansea University Medical School, for
experimentation.
Nonsaponiﬁable lipids were extracted as previously reported (29) and were derivatized with 0.1 ml
N,O-bis(trimethylsilyl)triﬂuoroacetamide:trimethylchlorosilane (99:1) and 0.3 ml anhydrous pyridine (2 h
at 80°C) prior to analysis by gas chromatography-mass spectrometry (38). Sterol composition was
calculated using peak areas from the gas chromatograms, and the mass fragmentation patterns
compared to known standards were used to conﬁrm sterol identity. The sterol contents of A. fumigatus
(basal) and treated A. fumigatus (treated with either DMSO, posaconazole, or PC945) were determined.
A. fumigatus cell-based ergosterol assay. Growth medium (RPMI 1640, 2 mM L-glutamine, 2%
glucose, 0.165 M MOPS, 0.5% BSA, pH 7.0) was added across a 96-well plate, and test agents were added
in duplicate. A. fumigatus (NCPF2010) conidia were added across the plate to a ﬁnal concentration of 1
104 ml1. After incubation for 24 h at 35°C, medium was removed from all wells and replaced with
reaction buffer (Amplex red cholesterol assay kit; Thermo Fisher) and Amplex red solution. Plates were
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incubated for 30 min at 37°C, protected from light, after which ﬂuorescence was quantiﬁed using a
spectrophotometer. Medium was removed from all wells and replaced with crystal violet solution (1%
[vol/vol]), and plates were incubated at room temperature on a shaker for 30 min. Plates were washed
three times with phosphate-buffered saline (PBS), and sodium dodecyl sulfate solution (0.1% [vol/vol])
was added across the plate to lyse the cells. After incubation at room temperature for 1 h, the absorbance
was measured by determining the OD590 by use of a spectrophotometer.
Fluorescence imaging of A. fumigatus-infected cells. Human alveolar epithelial cells (A549) were
seeded onto collagen-coated coverslips and incubated at 37°C and 5% CO2 for 24 h. Cells were
incubated in the presence of test agents for 2 h, after which the medium was replaced and the
coverslips were incubated at 37°C and 5% CO2 for 24 h. CellTracker red CMTPX dye (Thermo Fisher)
was added to the cell medium for 30 min, the wells were washed with PBS, and green ﬂuorescent
protein (GFP)-expressing A. fumigatus conidia (a kind gift from William Hope, University of Liverpool)
were added to wells to a ﬁnal concentration of 1  103 spores ml1. After 24 h of incubation at 35°C
and 5% CO2, coverslips were washed and afﬁxed to slides by use of Fluoroshield with DAPI
(4=,6-diamidino-2-phenylindole) (Sigma).
In vitro antifungal activity against A. fumigatus. Assessment of antifungal activity against a
selection of A. fumigatus laboratory/clinical strains (NCPF2010 [National Collection of Pathogenic Fungi
{NCPF}, Bristol, United Kingdom], AF72 [NCPF, Bristol, United Kingdom], AF91 [NCPF, Bristol, United
Kingdom], AF293 [NCPF, Bristol, United Kingdom], AF294 [NCPF, Bristol, United Kingdom], and TR34/L98H
[Bretagne, St. Louis Hospital, Paris, France]) was performed according to the method in the European
Committee on Antimicrobial Susceptibility Testing (EUCAST) deﬁnitive document EDef 9.3 (39), with the
following exceptions: (i) 0.5% BSA was added to the growth medium to avoid any loss of lipophilic
compounds by adherence to plastic plate surfaces and (ii) 384-well plates were used rather than 96-well
plates. Growth medium (RPMI 1640, 2 mM L-glutamine, 2% glucose, 0.165 M MOPS, 0.5% BSA, pH 7.0) was
added across the plate, test agents were added in quadruplicate, and the DMSO concentration was
identical across the plates. Conidia were added across the plate to a ﬁnal concentration of 1  105 ml1.
Plates were incubated for 48 h at 35°C, after which turbidity was assessed by measuring the OD530 by use
of a spectrophotometer, and the IC50 and IC90 values were calculated from the concentration-response
curve generated for each test compound by use of a four-parameter logistic equation (Dotmatics,
Bishops Stortford, United Kingdom). A. fumigatus ATCC 204305 was used as the assay control. Determi-
nation of antifungal activity against 50 A. fumigatus clinical isolates from St. Louis Hospital (Paris, France)
was performed with 96-well plates, using the modiﬁed EUCAST method in the presence of 0.5% BSA as
described above. Antifungal susceptibility testing of 46 A. fumigatus isolates (obtained from the NW
England Mycology Reference Centre) was performed by Evotec UK Ltd. (Manchester, United Kingdom)
according to EUCAST guidelines. Assessment of the antifungal activity against 4 of the A. fumigatus
strains (ATCC 1028, ATCC 10894, ATCC 13073, and ATCC 16424) was performed by Euroﬁns Panlabs
Taiwan Ltd. (Taipei, Taiwan) according to methodology described by the Clinical and Laboratory
Standards Institute (CLSI).
In vitro antifungal activity against other fungal species. For the measurement of activity against
Cryptococcus gattii, the method described in EUCAST deﬁnitive document EDef 7.2 was used, and assay
plates were incubated statically at 37°C in ambient air for 24 h (2 h) unless poor growth necessitated
further incubation to 36 or 48 h (40). Antifungal potency against Aspergillus ﬂavus, Aspergillus niger, and
Aspergillus terreus was determined as set out in EUCAST deﬁnitive document EDef 9.2, and assay plates
were incubated at 37°C for 48 h (41). These tests were conducted at Evotec UK Ltd. (Manchester, United
Kingdom). Measurement of activity against other fungi was performed by Euroﬁns Scientiﬁc according
to methodology described by the CLSI (document M38-A [42] or M27-A2 [43]).
In vitro determination of persistence of action on A. fumigatus hyphae. The persistence of action
of test agents was calculated for A. fumigatus hyphae (NCPF2010). Conidia were diluted in growth
medium (RPMI 1640, 2 mM L-glutamine, 2% glucose, 0.165 M MOPS, pH 7.0) and added across a 384-well
plate to a ﬁnal concentration of 1  103/well. After incubation at 35°C for exactly 6 h, test and reference
articles or undiluted DMSO (as vehicle) (0.5 l/well) was added to the appropriate wells to give a ﬁnal
concentration of 0.5% DMSO. The plates were incubated for exactly 20 min at 35°C and 5% CO2. After
the incubation time had elapsed, all wells on the designated washout plate were aspirated, and growth
medium (100 l/well) was added across the plate. For the nonwashout plate, no medium change was
applied after compounds were added to hyphae. Resazurin (0.04%; diluted in growth medium) was
added to all wells of both nonwashout and washout plates (5 l/well) to give a ﬁnal concentration of
0.002% resazurin. The plates were incubated at 35°C and 5% CO2 for 16 h. Subsequently, the ﬂuorescence
in each well was measured at 545/600 nm (ex/em) by use of a multiscanner (Clariostar; BMG,
Buckinghamshire, United Kingdom). The percent inhibition for each well was calculated, and the IC50 was
calculated from the concentration-response curve generated for each test compound by use of a
four-parameter logistic equation (Dotmatics, Bishops Stortford, United Kingdom).
In vitro determination of persistence of action on bronchial epithelial cells. The persistence of
action of test agents was evaluated on immortalized bronchial epithelial cells (BEAS2B cells). Each
experiment consisted of one nonwashout plate (96 wells) and a parallel washout plate, into which
BEAS2B cells were seeded at a concentration of 3  104 cells/well in growth medium (RPMI 1640, 2 mM
L-glutamine, 10% fetal calf serum [FCS]) and then incubated for 24 h at 37°C and 5% CO2. Test and
reference articles or undiluted DMSO (as vehicle) (0.5 l/well) was added to the appropriate wells of the
washout plate to give a ﬁnal concentration of 0.5% DMSO. The plate was incubated for exactly 1 h at 37°C
and 5% CO2. After the incubation time had elapsed, all wells on the washout plate were aspirated, and
growth medium (100 l/well) was added across the plate. After 24 h of incubation at 37°C, test and
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reference articles or undiluted DMSO (as vehicle) (0.5 l/well) was added to the appropriate wells of the
nonwashout plate to give a ﬁnal concentration of 0.5% DMSO. The plate was incubated for exactly 1 h
at 37°C and 5% CO2, after which A. fumigatus conidia were added across both plates to a ﬁnal
concentration of 1  103/well. Fungal growth was determined after a further 24 h of incubation at 35°C
and 5% CO2, by measuring galactomannan (GM) concentrations by use of Platelia GM-EIA kits (Bio-Rad
Laboratories). The percent inhibition for each well was calculated, and the IC50 was calculated from the
concentration-response curve generated for each test compound by use of a four-parameter logistic
equation (Dotmatics, Bishops Stortford, United Kingdom).
In vivo antifungal activity against A. fumigatus infection. Speciﬁc-pathogen-free A/J mice (male,
5 weeks old) were purchased from Sankyo Labs Service Co. Ltd. (Tokyo, Japan) and adapted for 1 week
in a temperature (24  1°C)- and humidity (55%  5%)-controlled room under a 12-h day-night cycle.
The mice were reared on a standard diet and tap water ad libitum. A/J mice were used for A. fumigatus
infection and proved to be infected more efﬁciently, as described previously (44). Animals were then
dosed with hydrocortisone (Sigma) (125 mg/kg of body weight administered subcutaneously) on days 3,
2, and 1 before infection and with cyclophosphamide (Sigma) (250 mg/kg administered intraperitoneally)
2 days before infection to induce temporary neutropenia, as previously reported (45). To avoid bacterial
infection, drinking water was supplemented with tetracycline hydrochloride (Sigma) (1 g/ml) and
ciproﬂoxacin (Fluka) (64 g/ml). A. fumigatus (ATCC 13073 [strain NIH 5233]; American Type Culture
Collection, Manassas, VA) was grown on malt agar (Nissui Pharmaceutical, Tokyo, Japan) plates for 6 to
7 days at room temperature (24  1°C). Conidia were aseptically dislodged from the agar plates and
suspended in sterile distilled water with 0.05% Tween 80 and 0.1% agar. On the day of infection, conidial
counts were assessed by use of a hemocytometer, and the inoculum was adjusted to obtain a
concentration of 1.67  108/ml in physiological saline. On day 0, 30 l of the conidial suspension was
administered intranasally.
Test agents suspended in physiological saline were administered daily intranasally (35 l) on days 1
to 6, and the survival of animals was recorded for 7 days. The volume inserted intranasally has been
reported to achieve almost 60% deposition into the lung (46). Deaths and the body weights of surviving
animals were monitored daily. A body weight loss of 20% compared to an animal’s weight on day 1
and mouse death were both deﬁned as “dropout” events. Animals that lost 20% of their initial body
weight were sacriﬁced. It was observed that A. fumigatus infection induced a “rolling” behavior, which
was monitored and recorded (17). Bronchoalveolar lavage ﬂuid (BALF) was collected on day 7 postin-
fection or on the day that the mouse dropped out of the study. The Aspergillus GM concentration in BALF
was determined by use of Platelia GM-EIA kits (Bio-Rad Laboratories). The value was provided as the
“cutoff index” (COI), which was calculated by the following formula: COI  OD in sample/OD in cutoff
control (provided by the kit). All animal studies were approved by the Ethics Review Committee for
Animal Experimentation of Nihon University. A. fumigatus studies were approved by the Microbial Safety
Management Committee of the Nihon University School of Pharmacy (protocol E-H25-001).
Statistical analysis. Results are expressed as means  standard errors of the means (SEM). Survival
analysis was performed by Kaplan-Meier plotting followed by log rank (Mantel-Cox) tests, using the Prism
6 software program (GraphPad Software Inc., San Diego, CA). For comparison between groups, either
ordinary one-way analysis of variance (ANOVA) with Tukey’s post hoc comparison or Kruskal-Wallis
ANOVA with Dunn’s post hoc comparison was performed. Statistical signiﬁcance was deﬁned for P values
of 0.05.
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